Modality
Peptide
MOA
CDK2i
Target
AuroraA
Pathway
JAK/STAT
T2DMMHuntington's
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
Sep 2019
→ Jan 2031
Phase 2Current
NCT06390070
824 pts·T2D
2019-09→2030-10·Not yet recruiting
NCT07504852
1,742 pts·Huntington's
2020-10→2031-01·Not yet recruiting
2,566 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-10-144.5y awayPh2 Data· T2D
2031-01-254.8y awayPh2 Data· Huntington's
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Not yet…
P2
Not yet…
Catalysts
Ph2 Data
2030-10-14 · 4.5y away
T2D
Ph2 Data
2031-01-25 · 4.8y away
Huntington's
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06390070 | Phase 2 | T2D | Not yet recr... | 824 | EFS |
| NCT07504852 | Phase 2 | Huntington's | Not yet recr... | 1742 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |